Experienced in Trichohepatoenteric Syndrome

Dr. Evan S. Dellon

Gastroenterology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Accepting New Patients
Experienced in Trichohepatoenteric Syndrome
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Evan Dellon is a Gastroenterologist in Chapel Hill, North Carolina. Dr. Dellon is rated as an Experienced provider by MediFind in the treatment of Trichohepatoenteric Syndrome. His top areas of expertise are Eosinophilic Esophagitis, Esophagitis, Eosinophilic Enteropathy, Endoscopy, and Colonoscopy. Dr. Dellon is currently accepting new patients.

His clinical research consists of co-authoring 526 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in NC
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514
Other Locations
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
300 Meadowmont Village Cir, Chapel Hill, NC 27517
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
100 Eastowne Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2024
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms
A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug, Other
Study Drug: Mepolizumab
Study Phase: Phase 2
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Enrollment Status: Completed
Publish Date: September 28, 2021
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Enrollment Status: Completed
Publish Date: May 26, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Enrollment Status: Completed
Publish Date: April 27, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)
A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)
Enrollment Status: Terminated
Publish Date: October 18, 2019
Intervention Type: Device, Procedure
Study Phase: Not Applicable
Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects
Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects
Enrollment Status: Terminated
Publish Date: January 17, 2018
Intervention Type: Procedure
View 11 Less Clinical Trials

525 Total Publications

Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis.
Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis.
Journal: NEJM evidence
Published: September 23, 2025
Similar Doctors
Distinguished in Trichohepatoenteric Syndrome
Dr. Mukesh Patel
Gastroenterology
Distinguished in Trichohepatoenteric Syndrome
Dr. Mukesh Patel
Gastroenterology

Danville Gastroenterology Center PC

600 Cleveland St, 
Danville, VA 
 (51.4 miles away)
434-791-1152
Languages Spoken:
English
See accepted insurances

Mukesh Patel is a Gastroenterologist in Danville, Virginia. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Trichohepatoenteric Syndrome. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Painful Swallowing, Swallowing Difficulty, Gastrectomy, and Gastrostomy.

Distinguished in Trichohepatoenteric Syndrome
Dr. Kurt Vernon
Gastroenterology
Distinguished in Trichohepatoenteric Syndrome
Dr. Kurt Vernon
Gastroenterology
904 W Broad St, Suite D, 
Dunn, NC 
 (47.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kurt Vernon is a Gastroenterologist in Dunn, North Carolina. Dr. Vernon is rated as a Distinguished provider by MediFind in the treatment of Trichohepatoenteric Syndrome. His top areas of expertise are Gastric Dysmotility, Gastroesophageal Reflux Disease (GERD), Colitis, and Swallowing Difficulty.

Distinguished in Trichohepatoenteric Syndrome
Dr. Christopher P. Jordan
Gastroenterology
Distinguished in Trichohepatoenteric Syndrome
Dr. Christopher P. Jordan
Gastroenterology

Duke Raleigh Hospital

3400 Wake Forest Rd, 
Raleigh, NC 
 (24.8 miles away)
919-954-3000
Experience:
30+ years
Languages Spoken:
English
See accepted insurances

Christopher Jordan is a Gastroenterologist in Raleigh, North Carolina. Dr. Jordan has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of Trichohepatoenteric Syndrome. His top areas of expertise are Painful Swallowing, Swallowing Difficulty, Familial Adenomatous Polyposis, and Diarrhea.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dellon's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 7 Advanced Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile